Home
About
Pricing
Log In
Back
ARX
Asset Logo

Aroa Biosurgery Limited

🇦🇺 ASX

🧬 BIOTECHNOLOGY

Compare
Add to watchlist
👑 Overview

📈 Performance

💵 Cost

🤓 Advanced

👨‍👩‍👧‍👦 Community

📈

-9.60%
Annual Growth

5 years average annual capital growth

💵

$ 500
Minimum Order

Due to regulatory requirements

🌏

13
Pearlers Invested

Since January 2020

👑 Overview

Key information
🔎 Fund Overview

Aroa Biosurgery Ltd. engages in the development, manufacturing, and marketing of soft tissue repair products. The company develops, manufactures, sells, and distributes medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Its products are developed from the AROA extracellular matrix (ECM) technology platform, an extracellular matrix biomaterial derived from the ovine forestomach. AROA ECM is an ECM biomaterial containing a rich and complex mix of biological molecules that serve as the building blocks for a range of soft tissue repair products. Its products include Endoform, Myriad Matrix, Myriad Morcells, Myriad Morcells Fine, Symphony, and Reinforced Bioscaffolds. Endoform products support all phases of wound healing and are appropriate for use early in wound management to restore protease balance and advance healing to the proliferative phase. Myriad Matrix is an engineered ECM designed for soft tissue repair, reinforcement, and complex wounds.

📈 Performance

Price History

-13.33%

1M

1Y

All Time

Graph

Table

Unsure how much or often to invest?
🗓️ Investing frequency calculator

Determine the investment frequency needed to reach your goals

Try it out →
💵 Investing amount calculator

Determine the recurring investment needed to reach your goals

Try it out →
⏱️ Investing duration calculator

Determine how long you will need to invest to reach your goals

Try it out →

💵 Costs

💵

6.50 AUD*
Purchase Fee

*$5.50 with Pearler Prepay

💼

N/A
Management Fee

Included in unit price, not charged by Pearler

💸

Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator

🤓 Advanced information

Technical Info

💰 Price*

$0.65

*Price may be up to 24 hours old

👩‍👩‍👦 Community Insights

How our community is investing

🌏 Pearlers invested in ARX

13

📊 Total Capital Earnings

$21K

🔃 Average investment frequency

18 weeks

💵 Average investment amount

$4,263

Last time a customer invested in ARX

12 days
ARX investor breakdown
💵 Income of investors

More than 200k

150k - 200k

100k - 150k

12%

50k - 100k

47%

Less than 50k

29%
👶 Age of investors

18 - 25

26 - 34

38%

35 - 90

62%
🙋 Legal gender of investors

Female

54%

Male

46%

Pearlers who invest in ARX also invest in...

Vanguard Australian Shares Index ETF

VAS

VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. The ETF currently has 21916.72m in AUM and 303 holdings. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.

🙌 Performance (5Yr p.a)

9.09%

📊 Share price

$110.92 AUD

💸 FINANCIALS

🧱 MATERIALS

🇦🇺 AUSTRALIA

⛳️ DIVERSIFIED

📈 HIGH PRICE GROWTH

Find Out More

Paladin Energy Ltd. engages in the development and operation of uranium mines. The company is headquartered in Perth, Western Australia. The firm also owns a portfolio of uranium exploration and development assets in the mining jurisdictions of Canada and Australia. Its segments include Australia, Namibia and Canada. The LHM is located in central western Namibia, approximately 80 kilometers (km) east of Swakopmund and 85 km northeast of the Walvis Bay deepwater harbor. Its Patterson Lake South (PLS) Project hosts the Triple R deposit, a high-grade and near-surface uranium deposit. The property comprises over 49 claims covering approximately 57,622 hectares. The company owns a number of greenfield exploration projects that are prospective for hosting high-grade uranium, including West Cluff, Larocque, Seahawk, Merlin, Corsair and Typhoon. Its projects also include Michelin (Labrador, Canada), Mount Isa and Manyingee projects in both Queensland and Western Australia.

🙌 Performance (5Yr p.a)

1095.00%

📊 Share price

$7.91 AUD

⚡️ ENERGY

Santos Ltd. engages in the exploration, development, transportation, and marketing of natural gas. The company is headquartered in Adelaide, South Australia and currently employs 3,958 full-time employees. Supporting these three business units are two functional divisions: Santos Energy Solutions and Upstream Gas and Liquids. The Cooper Basin produces natural gas, gas liquids and crude oil. Gas is sold primarily to domestic retailers, industry and for the production of liquefied natural gas, while gas liquids and crude oil are sold in domestic and export markets. Its GLNG project in Queensland produces liquefied natural gas (LNG) for export to global markets from the LNG plant at Gladstone and is also sold to the domestic market. Northern Australia and Timor-Leste is centered on the Bayu-Undan/Darwin LNG (DLNG) project.

🙌 Performance (5Yr p.a)

9.60%

📊 Share price

$7.80 AUD

📈 HIGH PRICE GROWTH

⚡️ ENERGY

Neuren Pharmaceuticals Ltd. engages in the development of new therapies for neurodevelopmental disorders that emerge in early childhood. The company is headquartered in Melbourne, Victoria. The company went IPO on 2005-02-03. The firm is developing new drug therapies to treat multiple serious neurological disorders that emerge in early childhood and have no or limited approved treatment options. The Company’s product DAYBUE (trofinetide) is used to treat Rett syndrome in adults and pediatric patients two years of age and older. The United States (US) Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have both granted orphan drug designation to the Company for trofinetide in Fragile X syndrome. Its second product NNZ-2591 is in phase II clinical trials in Phelan-McDermid syndrome, Angelman syndrome, Pitt Hopkins syndrome and Prader-Willi syndrome. The firm has granted an exclusive worldwide license to Acadia Pharmaceuticals Inc. for the development and commercialization of NNZ-259 for Rett syndrome and Fragile X syndrome.

🙌 Performance (5Yr p.a)

321.33%

📊 Share price

$20.48 AUD

📦 LOGISTICS

Lynas Rare Earths Ltd. engages in the production of rare earth minerals. The company is headquartered in Perth, Western Australia and currently employs 1,127 full-time employees. The Company’s operations include Mt Weld, Lynas Malaysia, Kalgoorlie and Lynas USA. The company focuses on developing the Mt Weld resource, which includes ongoing exploration, production of mixed rare earths concentrates, and an expansion project to increase concentrate feedstock production to support 12,000 tons per annum of finished NdPr oxide. The Lynas Malaysia advanced materials plant is located on a 100-hectare site in the Gebeng Industrial Estate, a purpose-built petrochemical industry zone near Kuantan, on the east coast of Malaysia. Its rare earths processing facility in Kalgoorlie undertakes value-added processing of rare earths. The firm's subsidiaries include Lynas Malaysia Sdn Bhd, Lynas Africa Ltd, Lynas Kalgoorlie Pty Ltd and Lynas USA LLC.

🙌 Performance (5Yr p.a)

98.60%

📊 Share price

$14.35 AUD

🕊️ SOCIALLY AWARE

⛏️ MINING

Want more shares? Try these...

ARXN

Compare
Add to watchlist